When the Food and Drug Administration approved the Ortho Evra Transdermal Birth Control Patch in November 2001, it became the first transdermal patch to effectively deliver a combination of norelgestromin and ethinyl estradiol, two vital hormones that help prevent unwanted pregnancy. The